非何杰金氏淋巴瘤治疗药物市场：现况分析与预测（2023-2030）

由于非何杰金氏淋巴瘤盛行率不断增加，预计在预测期内，非何杰金氏淋巴瘤治疗市场将以 7.7% 的复合年增长率强劲成长。 非何杰金氏淋巴瘤 (NHL) 是一种起源于淋巴系统的癌症，淋巴系统将淋巴液输送到全身。 其特征是淋巴球（白血球的一种）异常增生。 近年来，非何杰金氏淋巴瘤的盛行率在全球范围内稳步上升，对公众健康构成了重大挑战。 据美国癌症协会称，到 2023 年，大约 80,550 人（44,880 名男性和 35,670 名女性）将被诊断出患有非何杰金氏淋巴瘤。 根据欧洲癌症资讯系统（ECIS）的数据，预计2020年仅欧盟（EU）就会新增159,600例非何杰金氏淋巴瘤病例。

依治疗类型，市场分为化疗、放疗、标靶治疗和免疫治疗。 由于标靶治疗的采用增加、具有成本效益的生物仿製药的出现、对单株抗体的需求不断增加以及非何杰金氏淋巴瘤治疗的良好反应，免疫疗法将在2022 年占据很大的市场份额。 。 此外，临床试验数量的增加和製药公司投资的增加也支持了该行业未来一段时间的成长。

根据细胞类型，市场分为 B 细胞淋巴瘤和 T 细胞淋巴瘤。 由于多种驱动因素□□，B 细胞淋巴瘤细分市场在非何杰金氏淋巴瘤治疗市场中发挥重要作用。 首先，B细胞淋巴瘤的盛行率在非何杰金氏淋巴瘤的所有亚型中相对较高，这使其成为研究人员和製药公司至关重要的领域。 此外，对 B 细胞淋巴瘤分子和遗传特征的了解的进展促进了标靶治疗的发展。

依给药途径，市场分为口服剂和注射剂。 由于多种因素，注射剂部分在非何杰金氏淋巴瘤治疗市场中发挥重要作用。 首先，注射药物在便利性和给药方面具有显着的优势。 与口服药物不同，注射疗法可以由医疗保健专业人员直接给药，确保准确的剂量和最佳的药物传递。 这对于非何杰金氏淋巴瘤尤其重要，及时、准确的治疗至关重要。 其次，非何杰金氏淋巴瘤市场的注射药物通常包括标靶疗法和免疫疗法，这些疗法在治疗此类癌症方面显示出显着的疗效。

根据分销管道，市场分为医院药房、零售药房和网路药房。 预计线上药局产业在预测期内将以高复合年增长率成长。 有几个驱动因素促成了这一上升趋势。 首先，网路药局提供的便利性对其受欢迎程度起着关键作用。 患者不再需要前往实体店或诊所购买药品。 其次，网路药局通常比实体店提供更广泛的选择。 患者可以获得品牌药和仿製药，使他们能够选择适合自己特定要求和预算的选项。

为了更了解非何杰金氏淋巴瘤药物产业的市场介绍，市场为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区） ，亚太地区。根据地区（中国、日本、印度、亚太地区其他地区）、世界其他地区的存在进行分析。 2022年，北美拥有压倒性的市场份额。 近年来，北美非何杰金氏淋巴瘤的盛行率稳步上升，促进了治疗药物市场的成长。 老化、环境因素和遗传倾向等因素已被确定为这种增加的潜在原因。 该市场得到该地区成熟的医疗基础设施、先进的研究设施以及对医疗创新的重视的支持。 北美是多家着名製药公司的所在地，它们积极致力于新疗法和疗法的开发。

目录

第一章市场介绍

• 市场定义
• 主要目标
• 利害关係人
• 限制

第二章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章新型冠状病毒感染（COVID-19）对全球非何杰金氏淋巴瘤治疗药物市场的影响

第 6 章 2020-2030 年全球非何杰金氏淋巴瘤治疗药物市场收入

第 7 章按处理方式进行的市场洞察

• 化疗
• 放射治疗
• 标靶治疗
• 免疫治疗

第 8 章按电池类型划分的市场洞察

• B细胞淋巴瘤
• T细胞淋巴瘤

第 9 章依管理途径划分的市场洞察

• 口头
• 注射

第 10 章按通路划分的市场洞察

• 医院药房
• 零售药局
• 网路药局

第 11 章按地区划分的市场洞察

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区

第十二章非何杰金氏淋巴瘤治疗药物的市场动态

• 市场驱动因素
• 市场挑战
• 影响分析

第 13 章非何杰金氏淋巴瘤治疗的市场机会

第十四章非何杰金氏淋巴瘤治疗药物市场趋势

第十五章需求方与供给方分析

• 需求方分析
• 供给面分析

第16章价值链分析

第十七章竞争场景

• 波特五力分析
• 竞争状况

第十八章公司简介

• Merck KGaA
• BeiGene, Ltd.
• F. Hoffmann-La Roche Ltd
• Bristol Myers Squibb
• Eisai Co., Ltd.
• AstraZeneca
• Gilead Sciences
• Novartis AG
• Baxter
• Teva Pharmaceutical Industries Ltd.

第十九章免责声明

The non-Hodgkin lymphoma (NHL) therapeutics market is a rapidly growing sector in the healthcare industry, driven by advancements in research and development, as well as an increasing prevalence of NHL worldwide. Non-Hodgkin lymphoma refers to a group of cancers that originate in the lymphatic system, leading to abnormal growth of lymphocytes, which are white blood cells responsible for immune function. The market for NHL therapeutics has witnessed significant growth over the years, primarily due to the rising incidence of NHL globally. According to the American Cancer Society, it is estimated that approximately 81,560 new cases of NHL will be diagnosed in the United States alone in 2022. Moreover, factors such as an aging population and environmental factors contribute to the increasing prevalence of NHL, driving the demand for effective treatment options. Further, the development of personalized medicine and precision oncology has also significantly impacted the NHL therapeutics market.

The Non-Hodgkin Lymphoma Therapeutics Market is expected to grow at a strong CAGR of 7.7% during the forecast period owing to the growing prevalence of non-Hodgkin lymphoma. TNon-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is responsible for carrying lymph fluid throughout the body. It is characterized by the abnormal growth of lymphocytes, a type of white blood cell. The prevalence of non-Hodgkin lymphoma has been steadily increasing worldwide in recent years, posing significant challenges to public health. According to American Cancer Society, about 80,550 people (44,880 males and 35,670 females) will be diagnosed with NHL in 2023. This includes both adults and children As per the European Cancer Information System (ECIS), in 2020, there were an estimated 159,600 new cases of NHL in the European Union alone.

Based on therapy type, the market is categorized into chemotherapy, radiation therapy, targeted therapy, and immune therapy. The immune therapy held a significant share of the market in 2022, which is attributed to the increasing adoption of targeted therapy, the emergence of cost-effective biosimilars, increasing demand for monoclonal antibodies, and promising response in the treatment of non-Hodgkin lymphoma. In addition, rising number of clinical trials and growing investment by pharmaceutical companies is also driving the segment growth during the forthcoming period.

Based on cell type, the market is bifurcated into B-cell lymphoma and T-cell lymphoma. The B cell lymphoma segment plays a significant role in the non-Hodgkin lymphoma therapeutics market due to several driving factors. First and foremost, the incidence of B cell lymphoma is relatively high among all the subtypes of non-Hodgkin lymphoma, making it a crucial area of focus for researchers and pharmaceutical companies. Furthermore, advancements in understanding the molecular and genetic characteristics of B cell lymphomas have led to the development of targeted therapies.

Based on the route of administration, the market is bifurcated into oral and injectable. The injectable therapeutics segment plays a crucial role in the non-Hodgkin lymphoma therapeutics market, driven by several factors. Firstly, injectable therapeutics offer significant advantages in terms of convenience and administration. Unlike oral medications, injectable therapies can be directly administered by healthcare professionals, ensuring precise dosage and optimal drug delivery. This is especially important in non-Hodgkin lymphoma, where timely and accurate treatment is crucial. Secondly, injectable therapeutics in the non-Hodgkin lymphoma market often consist of targeted therapies and immunotherapies, which have shown remarkable efficacy in treating this type of cancer.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is anticipated to grow with high CAGR during the forecast period. Several driving factors contribute to this upward trend. Firstly, the convenience offered by online pharmacies plays a crucial role in their popularity. Patients no longer need to visit physical stores or clinics to purchase their medications. Secondly, online pharmacies often provide a wider range of products compared to brick-and-mortar stores. Patients can access both branded and generic medications, enabling them to choose options that fit their specific requirements and budget.

For a better understanding of the market adoption of the non-Hodgkin lymphoma therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share of the market in 2022. In North America, the prevalence of non-Hodgkin lymphoma has been steadily increasing in recent years, contributing to the growth of the therapeutics market. Factors such as the aging population, environmental factors, and genetic predisposition have been identified as potential causes for this rise. The market is supported by a well-established healthcare infrastructure, advanced research facilities, and a strong emphasis on medical innovation within the region. North America is home to several prominent pharmaceutical companies that actively contribute to the development of novel therapeutics and treatment modalities.

Some of the major players operating in the market include: Merck KGaA; BeiGene, Ltd.; F. Hoffmann-La Roche Ltd; Bristol Myers Squibb; Eisai Co., Ltd.; AstraZeneca; Gilead Sciences; Novartis AG; Baxter; and Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Non-Hodgkin Lymphoma Therapeutics Market
• 2.2. Research Methodology of the Non-Hodgkin Lymphoma Therapeutics Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET COVID-19 IMPACT

6 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY THERAPY TYPE

• 7.1. Chemotherapy
• 7.2. Radiation Therapy
• 7.3. Targeted Therapy
• 7.4. Immune Therapy

8 MARKET INSIGHTS BY CELL TYPE

• 8.1. B-Cell Lymphoma
• 8.2. T-Cell Lymphoma

9 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 9.1. Oral
• 9.2. Injectable

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 10.1. Hospital Pharmacies
• 10.2. Retail Pharmacies
• 10.3. Online Pharmacies

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. United States
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. France
  • 11.2.3. U.K.
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia Pacific
• 11.4. Rest of World

12 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET OPPORTUNITIES

14 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Porter's Five Forces Analysis
• 17.2. Competitive Landscape

18 COMPANY PROFILED

• 18.1. Merck KGaA
• 18.2. BeiGene, Ltd.
• 18.3. F. Hoffmann-La Roche Ltd
• 18.4. Bristol Myers Squibb
• 18.5. Eisai Co., Ltd.
• 18.6. AstraZeneca
• 18.7. Gilead Sciences
• 18.8. Novartis AG
• 18.9. Baxter
• 18.10. Teva Pharmaceutical Industries Ltd.

19 DISCLAIMER